Skip to main content
SpringerLink
Log in

Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction

  • Chapter
  • First Online:
Antithrombotic Drug Therapy in Cardiovascular Disease

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 1232 Accesses

Abstract

The central role of the platelet in the pathophysiology of acute coronary syndromes (ACS) has been well established. The significant morbidity and mortality associated with ACS has fostered great interest and effort in identifying various antiplatelet and antithrombotic regimens as well as developing novel agents in order to abrogate the platelet and its associated prothrombotic effects. Aspirin remains the integral component of all therapeutic strategies for ACS. When used in combination with thienopyridines (i.e., clopidogrel), GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban), or both, patients have experienced improved outcomes in this setting. However, with more potent antiplatelet regimens comes an increased risk of bleeding. Thus, the search for more potent antiplatelet agents with a decreased risk of bleeding continues for this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A (2002) Widespread coronary inflammation in unstable angina. N Engl J Med 347:5–12

    Article  PubMed  Google Scholar 

  2. Andre P, Denis CV, Ware J et al (2000) Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 96:3322–3328

    PubMed  CAS  Google Scholar 

  3. Eto K, Isshiki T, Yamamoto H et al (1999) AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 19:877–882

    Article  PubMed  CAS  Google Scholar 

  4. Goto S, Tamura N, Eto K, Ikeda Y, Handa S (2002) Functional significance of adenosine 5′-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation 105:2531–2536

    Article  PubMed  CAS  Google Scholar 

  5. Wagner AH, Guldenzoph B, Lienenluke B, Hecker M (2004) CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol 24:715–720

    Article  PubMed  CAS  Google Scholar 

  6. Andre P, Prasad KS, Denis CV et al (2002) CD40L stabilizes arterial thrombi by a beta3 integrin–dependent mechanism. Nat Med 8:247–252

    Article  PubMed  CAS  Google Scholar 

  7. Heeschen C, Dimmeler S, Hamm CW et al (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104–1111

    Article  PubMed  CAS  Google Scholar 

  8. Varo N, de Lemos JA, Libby P et al (2003) Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108:1049–1052

    Article  PubMed  CAS  Google Scholar 

  9. Ridker PM, Buring JE, Rifai N (2001) Soluble P-selectin and the risk of future cardiovascular events. Circulation 103:491–495

    Article  PubMed  CAS  Google Scholar 

  10. Lewis HD Jr, Davis JW, Archibald DG et al (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a veterans administration cooperative study. N Engl J Med 309:396–403

    Article  PubMed  Google Scholar 

  11. Cairns JA, Gent M, Singer J et al (1985) Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 313:1369–1375

    Article  PubMed  CAS  Google Scholar 

  12. (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 336:827–830

    Google Scholar 

  13. Theroux P, Ouimet H, McCans J et al (1988) Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319:1105–1111

    Article  PubMed  CAS  Google Scholar 

  14. Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP (2007) Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol 99:1212–1215

    Article  PubMed  Google Scholar 

  15. He J, Whelton PK, Vu B, Klag MJ (1998) Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 280:1930–1935

    Article  PubMed  CAS  Google Scholar 

  16. Gorelick PB, Weisman SM (2005) Risk of hemorrhagic stroke with aspirin use: an update. Stroke 36:1801–1807

    Article  PubMed  CAS  Google Scholar 

  17. Kurata JH, Abbey DE (1990) The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 12:260–266

    Article  PubMed  CAS  Google Scholar 

  18. Lee M, Cryer B, Feldman M (1994) Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 120:184–189

    PubMed  CAS  Google Scholar 

  19. FitzGerald GA, Oates JA, Hawiger J et al (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71:676–688

    Article  PubMed  CAS  Google Scholar 

  20. Kallmann R, Nieuwenhuis HK, de Groot PG, van Gijn J, Sixma JJ (1987) Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha excretion in healthy subjects. Thromb Res 45:355–361

    Article  PubMed  CAS  Google Scholar 

  21. Campbell CL, Smyth S, Montalescot G, Steinhubl SR (2007) Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297:2018–2024

    Article  PubMed  CAS  Google Scholar 

  22. Hallas J, Dall M, Andries A et al (2006) Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 333:726

    Article  PubMed  Google Scholar 

  23. Buresly K, Eisenberg MJ, Zhang X, Pilote L (2005) Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 165:784–789

    Article  PubMed  CAS  Google Scholar 

  24. Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86

    Article  Google Scholar 

  25. Peters RJ, Mehta SR, Fox KA et al (2003) Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation 108:1682–1687

    Article  PubMed  CAS  Google Scholar 

  26. (1991) A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med 325:1261–1266

    Google Scholar 

  27. Tickoo S, Roe MT, Peterson ED et al (2007) Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE quality improvement initiative. Am J Cardiol 99:1496–1499

    Article  PubMed  CAS  Google Scholar 

  28. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D (1998) Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 128:541–544

    PubMed  CAS  Google Scholar 

  29. Balsano F, Rizzon P, Violi F et al (1990) Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The studio della ticlopidina nell’angina instabile group. Circulation 82:17–26

    Article  PubMed  CAS  Google Scholar 

  30. Scrutinio D, Cimminiello C, Marubini E, Pitzalis MV, Di Biase M, Rizzon P (2001) Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 37:1259–1265

    Article  PubMed  CAS  Google Scholar 

  31. Bhatt DL, Bertrand ME, Berger PB et al (2002) Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 39:9–14

    Article  PubMed  CAS  Google Scholar 

  32. (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329–1339

    Google Scholar 

  33. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B (2000) Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 101:2823–2828

    Article  PubMed  CAS  Google Scholar 

  34. Steinhubl SR, Berger PB, Mann JT III et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420

    Article  PubMed  CAS  Google Scholar 

  35. Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607–1621

    Article  PubMed  CAS  Google Scholar 

  36. Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179–1189

    Article  PubMed  CAS  Google Scholar 

  37. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502

    Article  PubMed  CAS  Google Scholar 

  38. Di Nisio M, Bijsterveld NR, Meijers JC, Levi M, Buller HR, Peters RJ (2005) Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes. J Am Coll Cardiol 46:1582–1583

    Article  PubMed  Google Scholar 

  39. Yusuf S, Mehta SR, Zhao F et al (2003) Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107:966–972

    Article  PubMed  CAS  Google Scholar 

  40. Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533

    Article  PubMed  CAS  Google Scholar 

  41. Lewis BS, Mehta SR, Fox KA et al (2005) Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Am Heart J 150:1177–1184

    Article  PubMed  CAS  Google Scholar 

  42. McFadden EP, Stabile E, Regar E et al (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364:1519–1521

    Article  PubMed  CAS  Google Scholar 

  43. Nasser M, Kapeliovich M, Markiewicz W (2005) Late thrombosis of sirolimus-eluting stents following noncardiac surgery. Catheter Cardiovasc Interv 65:516–519

    Article  PubMed  Google Scholar 

  44. Pfisterer M, Brunner-La Rocca HP, Buser PT et al (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48:2584–2591

    Article  PubMed  CAS  Google Scholar 

  45. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356:1009–1019

    Article  PubMed  CAS  Google Scholar 

  46. Iakovou I, Schmidt T, Bonizzoni E et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130

    Article  PubMed  CAS  Google Scholar 

  47. Eisenstein EL, Anstrom KJ, Kong DF et al (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297:159–168

    Article  PubMed  CAS  Google Scholar 

  48. Spertus JA, Kettelkamp R, Vance C et al (2006) Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113:2803–2809

    Article  PubMed  CAS  Google Scholar 

  49. Boersma E, Harrington RA, Moliterno DJ et al (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359:189–198

    Article  PubMed  CAS  Google Scholar 

  50. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D (2004) Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 292:362–366

    Article  PubMed  CAS  Google Scholar 

  51. Kastrati A, Mehilli J, Neumann FJ et al (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295:1531–1538

    Article  PubMed  CAS  Google Scholar 

  52. Greenbaum AB, Grines CL, Bittl JA et al (2006) Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 151:689 e1–689 e10

    Article  Google Scholar 

  53. Jacobsson F, Swahn E, Wallentin L, Ellborg M (2002) Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 24:752–765

    Article  PubMed  CAS  Google Scholar 

  54. A clinical trial comparing cangrelor to clopidogrel in subjects who require percutaneous coronary intervention (CHAMPION-PCI). Available at http://clinicaltrials-nccs.nlm.nih.gov/ct/show/NCT00305162. Accessed 15 Nov 2007

  55. A clinical trial comparing treatment with cangrelor (in combination with usual care), in subjects who require percutaneous coronary intervention. Available at http://clinicaltrials-nccs.nlm.nih.gov/ct/show/NCT00385138. Accessed 15 Nov 2007

  56. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F (2005) Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 31:184–194

    Article  PubMed  CAS  Google Scholar 

  57. Brandt JT, Payne CD, Wiviott SD et al (2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153:66 e9–66 e16

    Article  Google Scholar 

  58. Matsushima N, Jakubowski JA, Asai F et al (2006) Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. Platelets 17:218–226

    Article  PubMed  CAS  Google Scholar 

  59. Asai F, Jakubowski JA, Naganuma H et al (2006) Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets 17:209–217

    Article  PubMed  CAS  Google Scholar 

  60. Wiviott SD, Antman EM, Winters KJ et al (2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIM 26 trial. Circulation 111:3366–3373

    Article  PubMed  CAS  Google Scholar 

  61. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015

    Article  PubMed  CAS  Google Scholar 

  62. Murphy SA, Antman EM, Wiviott SD et al (2008) Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 29(20):2473–2479

    Article  PubMed  CAS  Google Scholar 

  63. Protocol H7T-MC-TABL(a) PRasurgrel IN Comparison to Clopidogrel for Inhibition of PLatelet Activation and AggrEgation (PRINCIPLE) – TIMI 44. Available at http://clinicaltrials-nccs.nlm.nih.gov/ct/show/NCT00357968. Accessed 15 Nov 2007

  64. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27:1038–1047

    Article  PubMed  CAS  Google Scholar 

  65. A randomised, double-blind, parallel group, phase 3, efficacy and safety study of AZD6140 compared with clopidogrel for prevention of vascular events in patients with non-ST or ST elevation acute coronary syndromes (ACS) [PLATO- a study of PLATelet inhibition and patient outcomes]. Available at http://clinicaltrials-nccs.nlm.nih.gov/ct/show/NCT00391872. Accessed 15 Nov 2007

  66. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102:624–629

    Article  PubMed  CAS  Google Scholar 

  67. Bertrand ME, Legrand V, Boland J et al (1998) Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 98:1597–1603

    Article  PubMed  CAS  Google Scholar 

  68. Muller C, Buttner HJ, Petersen J, Roskamm H (2000) A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 101:590–593

    Article  PubMed  CAS  Google Scholar 

  69. Taniuchi M, Kurz HI, Lasala JM (2001) Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 104:539–543

    Article  PubMed  CAS  Google Scholar 

  70. Dangas G, Mehran R, Abizaid AS et al (2001) Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. Am J Cardiol 87:470–472 A7

    Article  PubMed  CAS  Google Scholar 

  71. Berger PB, Bell MR, Rihal CS et al (1999) Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 34:1891–1894

    Article  PubMed  CAS  Google Scholar 

  72. Stone GW, Moses JW, Ellis SG et al (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998–1008

    Article  PubMed  CAS  Google Scholar 

  73. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL (2006) Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119:1056–1061

    Article  PubMed  CAS  Google Scholar 

  74. Kastrati A, Mehilli J, Pache J et al (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030–1039

    Article  PubMed  CAS  Google Scholar 

  75. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020–1029

    Article  PubMed  CAS  Google Scholar 

  76. Airoldi F, Colombo A, Morici N et al (2007) Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116:745–754

    Article  PubMed  CAS  Google Scholar 

  77. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW (2005) Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45:2088–2092

    Article  PubMed  CAS  Google Scholar 

  78. (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 330:956–961

    Google Scholar 

  79. (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG investigators. N Engl J Med 336:1689–1696

    Google Scholar 

  80. Lincoff AM, Tcheng JE, Califf RM et al (1999) Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial.Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 99:1951–1958

    Article  PubMed  CAS  Google Scholar 

  81. (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349:1429–1435

    Google Scholar 

  82. Montalescot G, Barragan P, Wittenberg O et al (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344:1895–1903

    Article  PubMed  CAS  Google Scholar 

  83. Brener SJ, Barr LA, Burchenal JE et al (1998) Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98:734–741

    Article  PubMed  CAS  Google Scholar 

  84. Stone GW, Grines CL, Cox DA et al (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346:957–966

    Article  PubMed  CAS  Google Scholar 

  85. EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87–92

    Article  Google Scholar 

  86. Simoons ML (2001) Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357:1915–1924

    Article  PubMed  CAS  Google Scholar 

  87. (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 339:436–443

    Google Scholar 

  88. ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356:2037–2044

    Article  Google Scholar 

  89. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Impact II. Integrellin to Minimise Platelet Aggregation and Coronary Thrombosis II. Lancet 1997. May 17, 349(9063):1422–1428

    Google Scholar 

  90. (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators. N Engl J Med 338:1498–1505

    Google Scholar 

  91. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD (1999) Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM study investigators. Platelet receptor inhibition in ischemic syndrome management. Lancet 354:1757–1762

    Article  PubMed  CAS  Google Scholar 

  92. (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 338:1488–1497

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Western Reserve Heart Care, Hudson, OH, USA

    Saif Anwaruddin MD

  2. Department of Cardiology, VA Boston Healthcare System, and Integrated Interventional Cardiovascular Program, Brigham and Women’s Hospital, Boston, MA, USA

    Deepak L. Bhatt MD, MPH

Authors
  1. Saif Anwaruddin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deepak L. Bhatt MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepak L. Bhatt MD, MPH .

Editor information

Editors and Affiliations

  1. Western Reserve Heart Care, Corporate Dr. 1335, Hudson, 44236, U.S.A.

    Arman T. Askari

  2. Dept. Cardiovascular Medicine, Cleveland Clinic, Euclid Ave. 9500, Cleveland, 44195, U.S.A.

    A. Michael Lincoff

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Anwaruddin, S., Bhatt, D.L. (2010). Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction. In: Askari, A., Lincoff, A. (eds) Antithrombotic Drug Therapy in Cardiovascular Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-235-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-235-3_7

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-234-6

  • Online ISBN: 978-1-60327-235-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation